Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bower

Showing results (181-190 of 252) with videos related to

Pageof 26
Sort By:
Urologia Internationalis|October 27, 2010
The effect of sunitinib on immune subsets in metastatic clear cell renal cancerThomas Powles, Simon Chowdhury, Mark Bower, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
AIDS (London, England)|August 28, 2007
Risk of cancers during interrupted antiretroviral therapy in the SMART studyMichael J Silverberg, Jacqueline Neuhaus, Mark Bower, et al.
Antiviral Therapy|January 30, 2016
Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?Leah Shepherd, Álvaro H Borges, Lene Ravn, et al.
Discover Oncology|April 12, 2021
Anal squamous cell carcinoma in a high HIV prevalence populationDanielle R L Brogden, Christopher C Khoo, Christos Kontovounisios, et al.
The Journal of Investigative Dermatology|January 11, 2008
Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter studyGiuseppe Di Lorenzo, Alexander Kreuter, Rossella Di Trolio, et al.
Cell Host & Microbe|November 11, 2008
Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirusDimitrios Lagos, Richard James Vart, Fiona Gratrix, et al.
Nature Communications|January 22, 2021
Oncogenic herpesvirus KSHV triggers hallmarks of alternative lengthening of telomeresTimothy P Lippert, Paulina Marzec, Aurora I Idilli, et al.
BMC Cancer|July 2, 2025
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi's SarcomaClaudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, et al.
The New England Journal of Medicine|September 9, 2005
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomasMichael Cullen, Neil Steven, Lucinda Billingham, et al.
Pageof 26

Showing results (181-190 of 252) with videos related to

Sort By:
Pageof 26
Urologia Internationalis|October 27, 2010
The effect of sunitinib on immune subsets in metastatic clear cell renal cancerThomas Powles, Simon Chowdhury, Mark Bower, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
AIDS (London, England)|August 28, 2007
Risk of cancers during interrupted antiretroviral therapy in the SMART studyMichael J Silverberg, Jacqueline Neuhaus, Mark Bower, et al.
Antiviral Therapy|January 30, 2016
Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?Leah Shepherd, Álvaro H Borges, Lene Ravn, et al.
Discover Oncology|April 12, 2021
Anal squamous cell carcinoma in a high HIV prevalence populationDanielle R L Brogden, Christopher C Khoo, Christos Kontovounisios, et al.
The Journal of Investigative Dermatology|January 11, 2008
Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter studyGiuseppe Di Lorenzo, Alexander Kreuter, Rossella Di Trolio, et al.
Cell Host & Microbe|November 11, 2008
Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirusDimitrios Lagos, Richard James Vart, Fiona Gratrix, et al.
Nature Communications|January 22, 2021
Oncogenic herpesvirus KSHV triggers hallmarks of alternative lengthening of telomeresTimothy P Lippert, Paulina Marzec, Aurora I Idilli, et al.
BMC Cancer|July 2, 2025
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi's SarcomaClaudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, et al.
The New England Journal of Medicine|September 9, 2005
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomasMichael Cullen, Neil Steven, Lucinda Billingham, et al.
Pageof 26